Ekso Bionics reports Q4 EPS (14c) vs. (22c) last year

Reports Q4 revenue $5.09M, consensus $5.05M. “We are pleased to close out 2024 with record fourth quarter revenue, improved gross margin and growing interest in our unrivalled portfolio of Enterprise Health and Personal Health devices,” said Scott Davis, the company’s CEO. “Looking ahead, our focus will be on aggressively executing two key pillars of our growth strategy: broadening patient access to Ekso Indego Personal and building upon our growing CMS claim pipeline for the device; and further bolstering demand for our legacy EksoNR device. We look forward to updating investors as we progress.”